Joao Gamelas Magalhaes
Science Lead, Immuno-Oncology

Marcus Rauch
Chief Scientific Officer

Marcus is a microbiologist with 18+ years of experience in academia and pharma. He focused his research interest on microbiome sciences while a staff scientist at the University of California, San Francisco. More recently, as a Principal Scientist at Janssen and Head of a microbiome lab, he led a cross-disciplinary team and successfully built and managed internal & external collaborations. He co-founded AlphaBiomics in 2018 and serves as the company’s CSO.

Steve Cox
Anaerobe Systems

Deepak Gopalakrishnan
Scientist - Microbiome Discovery

Mark Bamforth
President & CEO
Arranta Bio

Mark Bamforth founded a new CDMO, Arranta Bio, in May 2019. Previously, Mark founded Brammer Bio in 2015, a best-in-class viral vector contract development and manufacturing organization (CDMO) supporting cell and gene therapies. Brammer’s team grew from 110 in 2016 with the addition of 100 from the acquisition of two Biogen commercial facilities, to over 600 at the time of its acquisition by Thermo Fisher Scientific in April 2019. In 2010, Mark founded a biologics CDMO, Gallus BioPharmaceuticals, and acquired a world-class facility and team of 160 from J&J with a commercial supply agreement. Gallus tripled through organic growth and merging with Laureate Biopharma. Gallus was sold to DPx Holdings B.V. in Sept. 2014. Mark previously spent 22 years in the UK and USA running a global manufacturing operation and a pharmaceutical CMO business for Genzyme and served as a corporate officer for 9 years. He began his career as a petroleum engineer exploring for North Sea oil with Britoil, then as a chemical engineer in the whisky industry with Whitbread. Mark serves on the boards of Avid Bioservices, MassBio, Wentworth Institute of Technology, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.

Day Two

Thursday 13th December 2018

10:00 am | Advances in Meeting the Microbiome Supply Needs

Jackie Papkoff
Chief Scientific Officer
Assembly Biosciences

Dr. Papkoff joined Assembly Bio in April 2018 to lead the microbiome therapeutic programs. She has worked in both pharma and biotech for over 25 years and has broad scientific strategy, executive leadership and business experience. She has deep expertise in cell biology and molecular mechanisms of disease which she has applied to therapeutic and biomarker preclinical discovery & development in oncology, inflammation and autoimmunity. Prior to joining Assembly Biosciences, Dr. Papkoff was Senior Vice President of Research at Evelo Biosciences where she led the preclinical scientific team to discover, validate and nominate microbial therapeutics for clinical development in oncology indications. Prior to Evelo Dr. Papkoff was a founding member of the J&J California Innovation Center where she served as Vice President of Immunology Scientific Innovation for the Janssen Immunology Therapeutic Area focused on inflammatory and autoimmune diseases. Previously, she was CSO of CFD Therapeutics, a cancer-immunology focused antibody therapeutics company she co-founded, and held R&D leadership positions at diaDexus, Inc. and Aventis pharma. Beyond her industry career Dr. Papkoff was a Consulting Professor of Cancer Biology at Stanford for a 10-year period and served terms as grant reviewer as well as Advisory Council Member for the California Breast Cancer Research Program. Dr. Papkoff has a B.A in Biology from University of California Santa Cruz, a PhD in Biology from University of California San Diego & the Salk Institute and was a postdoctoral fellow at Stanford and University of California San Francisco.

David Donabedian
Axial Therapeutics

Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience. Dr. Donabedian has a track record of building companies, most recently as a Venture Partner at Longwood Fund. Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie and GSK. At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture’s Strategic Services Consulting Group. He holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.

Assaf Oron
Chief Business Officer

Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. At Evogene, he worked in various roles such as executive vice president of corporate development and executive vice president of strategy and business development. From 2004 to 2006, Mr. Oron served as CEO of ChondroSite Ltd., a biotechnology company that develops engineered tissue products in the field of orthopedics. From 1999 to 2003, Mr. Oron was a senior project manager and strategic consultant at POC Ltd., a leading Israeli management consulting company. Mr. Oron holds an M.Sc. in Biology (bioinformatics) and a B.Sc. in Chemistry and Economics, both from Tel Aviv University.

Morten Isaksen

Martha Carlin
CEO & Co-Founder
The BioCollective

Mathieu Bey
Project Manager
Biose Industrie

Kathleen Brennan
Director Microbiology
Boston Analytical

Day One

Thursday 13th December 2018

9:15 am | Gut Microbiome Endgame: Ramping up cGMP Program Design to Ensure Regulatory Preparedness for Microbiome Products

Luc Sterkman
Caelus Health

Luc Sterkman, MD (CEO) obtained his medical degree (MD) in 1988 at the Free University in Amsterdam. He has broad experience in the fields of general management, business development and R&D. From 1992-2002 he was COO and later CEO of U-Gene Research, that was successfully sold to Kendle USA (NASDAQ –KNDL). From 2002 to 2004, he worked as a Board member of the biotech company OctoPlus and from 2005 to 2010 he was General manager at the pharmaceutical company Disphar International BV (part of the Nordic Group). From 2011-2016 he worked as a COO at Newtricious, which company is focusing on innovative nutrition and functional foods. As the CEO at Caelus Health, he is since January 2016 overall responsible for building and directing the company in the next phase of growth and further expanding its pipeline of new microbiota-based products in the field of cardio-metabolic diseases.

Stephen Conafay
Principal & Founder
Conafay Group

Steve Conafay has 35 years of leadership and management experience in government relations, public policy and communications. As the sole principal at The Conafay Group, he oversees all client servicing. While leader of the bio-life science practice at Fabiani & Company, he oversaw more than $810 million in non-dilutive financing awarded to the team’s clients. For 12 years, Mr. Conafay was vice president of government relations for Pfizer, where he was elected as a corporate officer in 1984. He served as senior vice president of corporate affairs for Glaxo Inc., where he was also a member of the Board of Directors. After heading the legislative practice for Jones, Day, Reavis and Pogue, the world’s second largest law firm, he was tapped by the Pharmaceutical Research and Manufacturers of America (PhRMA) to assume the No. 2 position of executive vice president of strategic and legislative affairs. He also served as an executive fellow at the American Enterprise Institute, the leading free market think tank in the U.S. After moving to the New York area, Mr. Conafay joined Shandwick, where he assumed several positions of increasing responsibility, culminating with his appointment as chief executive officer for The Americas-East in 2000. Mr. Conafay is a lawyer and a decorated Vietnam veteran. He served as an infantry platoon leader and was awarded the Silver Star, Bronze Star with Oak Leaf Cluster, the Air Medal and the Army Commendation Medal, among others. He is also an avid golfer and has been a member of Congressional Country Club for more than 30 years. Mr. Conafay is a lifelong fan of the New York and San Francisco Giants. In his 60s, he ran and completed four Army 10-miler races, and plans to continue competing in his 70s.

Day Two

Thursday 13th December 2018

9:30 am | Updates from the Microbiome Therapeutics Innovation Group (MTIG) – Building a Collective Voice to Enhance the Regulatory, Investment and Commercial Success of Microbiome-Based Therapeutics

Dan Knights

Dan Knights is a computer scientist, computational biologist, and globally recognized expert in microbiome informatics who has developed some of the leading methods for analyzing microbiome data. He directs informatics & software development at CoreBiome, and was educated at Middlebury, University of Colorado, and Harvard Medical School.

Day Two

Thursday 13th December 2018

10:30 am | A Trifecta in Microbiome Advancements: Expectations from the Partnership of Diversigen, Corebiome and DNA Genotek

Arne Materna
Vice President Product

Day One

Thursday 13th December 2018

9:45 am | Shotgun Sequencing & Strain-Level Analysis: Study Design for Pre-Clinical & Clinical Development

Gerard Honig
Associate Director, Research Innovation
Crohn’s & Colitis Foundation

Aaron Del Duca
VP Microbiome Platform

Mark Smith
Finch Therapeutics

Day One

Thursday 13th December 2018

8:30 am | Microbiome Leaders Panel Discussion

Sonia Timberlake
VP Research
Finch Therapeutics

Dr. Sonia Timberlake is the VP of Research at Finch Therapeutics, a microbiome therapeutics company. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology. Sonia graduated from Caltech with a B.Sc in Molecular Biology and received her Ph.D. in Biological Engineering from MIT.

Daniel van der Lelie
Chief Scientific Officer
Gusto Global

Daniel van der Lelie is the Chief Scientific Officer and Co-Founder of Gusto Global, a leading microbiome drug discovery and development company focused on the rational design of live biotherapeutics that modulate the immune system. Dr. van der Lelie has worked in senior management roles in biotechnology, agriculture, environmental sciences and on the interface between biological sciences and nanotechnology throughout his career. Dr. van der Lelie’s research has resulted in more than 150 publications in peer reviewed journals, including PLoS ONE, PLoS Genetics, Nature, Nature Chemistry, Nature Nanotechnology and Nature Biotechnology, and 27 patents / patent applications.

Johan van Hylckama Vlieg
Chief Scientific Officer
Kaleido Biosciences

Dr. van Hylckama Vlieg has served as Kaleido's Chief Scientific Officer since July 2019. Dr. van Hylckama Vlieg has 25 years of experience leading teams and R&D programs in gut microbiology, probiotics and live biotherapeutics, and industrial biotechnology in industry and academia. Most recently, he served as Vice President for Microbiome and Human Health Innovation at Chr. Hansen in Denmark, responsible for new strain development for probiotic and therapeutic application, spanning discovery to clinical development and novel technology platforms. Previously, Dr. van Hylckama Vlieg worked at Danone Research and in several roles at NIZO Food Research. He completed his Ph.D. and post-doc in biochemistry at the University of Groningen in the Netherlands.

Mike Bonney
Kaleido Biosciences

Day One

Thursday 13th December 2018

8:30 am | Microbiome Leaders Panel Discussion

Stacy Burns-Guydish
List Laboratories

Jason Ryan
Head of Upstream
Luina Bio

Geoffrey Hannigan
Associate Principal Scientist
Merck Exploratory Science Center

Gunjan Singh Thakur
Senior Scientist Computational Biology
Merck Exploratory Science Center

Xue Liang
Microbiome Scientist
Merck Exploratory Science Center

Blake Wise
Novome Biotechnologies

Nurry Hong
Pareto Bio

Colleen Cutcliffe
Co-founder & CEO
Pendulum Therapeutics

Colleen Cutcliffe is the CEO and Co-Founder of Pendulum. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.

Mohan Iyer
Chief Operating Officer
Pendulum Therapeutics

Fabio Spreafico
Pharma Account

Ryan Wilson
Head of Live-Bioprogrammes
Quay Pharma

Steven Bass
Senior Customer Solutions Manager, Genomics

Ken Blount

Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.

Day Two

Thursday 13th December 2018

9:30 am | Updates from the Microbiome Therapeutics Innovation Group (MTIG) – Building a Collective Voice to Enhance the Regulatory, Investment and Commercial Success of Microbiome-Based Therapeutics

Lee Jones

Day One

Thursday 13th December 2018

8:30 am | Microbiome Leaders Panel Discussion

Lindy Bancke
PharmD Head of Clinical Development

Barbara McGovern
MD, VP Medical Affairs
Seres Therapeutics

Barbara McGovern is VP of Medical Affairs at Seres. Dr. McGovern has over 25 years of experience in infectious diseases. Prior to joining Seres, she served as Medical Director in the Medical Affairs Division at AbbVie and helped to launch Viekera Pak for treatment of hepatitis C virus (HCV) infection. At AbbVie, Dr. McGovern was recipient of the “2015 President’s Award” in recognition of successful execution of 7 major publications in the New England Journal of Medicine, Lancet and JAMA. She also authored more than 50 journal articles, editorials, and textbook chapters on HIV and HCV and was an Associate Editor of Clinical Infectious Diseases. Dr. McGovern has also served as a member of the Antiviral Advisory Committee for FDA and as a panel guideline member for the Department of Health and Human Services. She earned her undergraduate degree from Queens College, CUNY, her M.D. at Albert Einstein College of Medicine and completed her internship, residency and infectious disease fellowship at Tufts Medical Center.

Eric Shaff
Seres Therapeutics

Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has more than 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. Prior to joining Seres, he was Vice President, Corporate Finance, at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning, and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance, of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Mr. Shaff held several positions at Genzyme in business unit finance, corporate finance, and corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies LLC). Mr. Shaff earned his B.A. from the University of Pennsylvania in political science and economics and his M.B.A. with a concentration in finance from the Johnson Graduate School of Management at Cornell University.

Day One

Thursday 13th December 2018

8:30 am | Microbiome Leaders Panel Discussion

Chris McChalicher
Senior Director, Technical Development
Seres Therapeutics

Eric Van der Helm
Head of Synthetic Biology & Bioinformatics

Gerardo Toledo
Co-Founder & CEO
Solarea Bio

Jeffrey Hymes

Jeff Hymes is passionate about the microbiome and its potential as an untapped source of novel drug targets. In 2016, he joined Symberix, a startup company pioneering a completely new class of small molecule drugs that selectively block harmful bacterial activity without disturbing the gut microbiota. As a scientist at Symberix, Jeff has expanded Symberix’s drug discovery platform, identified novel microbiome drug targets, and managed a research collaboration with the National Center for Advancing Translational Sciences (NCATS). Jeff has published multiple articles related to human-associated bacteria and the microbiome.

Yogesh Mudaliar
Research Investigator Drug Product Development
Takeda Pharmaceuticals

Yogesh Mudaliar is currently a Research Investigator at Takeda Pharmaceuticals, where he supports the lyophilization development of live microbiomes, monoclonal antibodies and antibody drug conjugates. After obtaining his Pharmacy degree, Mr. Mudaliar gained valuable professional experience in various pharmaceutical departments such as a science executive, in marketing, advertising etc. However, Mr. Mudaliar’s passion for R&D drove him back into grad school where he obtained his M.S. in Biological Sciences from University of Massachusetts. After graduation, Mr. Mudaliar obtained a position at Merck Millipore as a Bioanalytical Scientist, where he developed chromatography methods and performed characterization studies for biologics. He subsequently joined AstraZeneca as a Formulation Scientist gaining experience in formulation, process development and large scale manufacturing of lyophilized and liquid biological products from early through late stage development. His work on particle formation due post-lyophilization stability issues in monoclonal antibodies won him the Thomas Jennings award at the ISLFD 2016. Concurrently, during his time at AstraZeneca he also completed a professional learning course on Biotherapeutic Formulations from MIT. In 2018, Mr. Mudaliar joined Takeda Pharmaceuticals as a Research Investigator, to provide technical leadership for formulation development and lyophilization of LBP, antibodies, ADCs and fusion proteins. Currently, Mr. Mudaliar also serves on the company’s millennial advisory board to the CEO.

Gregory Lambert
CEO and VP R&D

A Pharmacist, with a PhD in pharmaceutical technology, Gregory’s career has been split between Biotech and Pharma as Chief Scientific Officer and Chief Executive Officer in companies such as Novagali Pharma, Septodont and currently TargEDys. Gregory has led the development of several products from the laboratory to the market. In 2014, Gregory joined the scientific founders of TargEDys as CEO. Having completed preclinical development and produced industrial batches, TargEDys now concentrates on human clinical trials and commercial launch activities.

Matthew Henn
Seres Therapeutics

Kate Sheridan

Day One

Thursday 13th December 2018

8:30 am | Microbiome Leaders Panel Discussion

Bernat Olle
Vedanta Biosciences

Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of several companies of the PureTech portfolio and served as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences. In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in the Republic of Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.

Day One

Thursday 13th December 2018

8:30 am | Microbiome Leaders Panel Discussion

Rose Szabady
Associate Director
Immunology Vedanta Biosciences

Ryan Toma
Research Scientist

Ryan is a Research Scientist at Viome, the leader in data-driven personalized nutrition. He focuses on designing and implementing clinical studies with the aim of harnessing Viome's personalized nutrition program to combat chronic diseases. Ryan is also a member of the R&D team at Viome and is involved in product development. Prior to joining Viome, Ryan was a key member of the Applied Genomics team at Los Alamos National Lab that developed the core technologies that Viome uses today. Viome's systems biology platform enables precise modulation of microbial functions and supplementation of missing human functions via nutritional interventions.

Rob van Dijk
Business Development Manager
Wacker Biotech

Travis Whitfill
Cofounder and Executive Director of Advanced Technology

Talia Jewell
Group Lead, Microbiology
GALT: General Automation Lab Technologies, Inc

Libusha Kelly
Associate Professor
Albert Einstein College of Medicine

Our basic research program develops new experimental and computational technologies to biologically organize and describe the dynamics of the tremendous genetic diversity in microbial communities. Microbes and viruses are first responders to alterations in the environment. Microbial responses to environmental changes include transcriptional, proliferative, and genomic changes little is known about how viruses respond to environmental perturbations in the context of interactions with their hosts. Furthermore, microbes and viruses exist in tight-knit networks that compete for, produce, and share resources. Microbial community structure/function relationships are poorly understood, which inhibits our ability to support or prevent particular functions. We develop new computational methods to 1) quantify genomic differences and interactions in microbial and viral populations and 2) characterize novel viruses. We recently reported in Nature a novel family of tailless viruses that are major unrecognized killers of marine viruses with the Polz lab at MIT (Kauffman, et al. 2017). These mysterious viruses are also found in the human microbiome, and we are in the process of characterizing their effects on microbial communities in the human body. If we understand how communities are organized and how they change over time under particular conditions, such as inflammation, we can better target microbes and genes to alter that condition.

Our translational research program provides patients and their doctors with actionable information about their microbiomes to improve health and treatment plans. For example, we recently discovered that microbiomes of different individuals have different capacities to activate irinotecan, an anti-cancer drug (Guthrie, et al, 2017). We linked this differential metabolism to specific microbial carbohydrate active enzymes. In mouse models, gut metabolism of irinotecan leads to adverse events, including severe diarrhea. We hypothesize that the life- threatening diarrhea that afflicts up to a quarter of metastatic colorectal cancer patients who take this drug might also be caused by microbial turnover, and are working with oncologists at Einstein/Montefiore to recruit and track patients receiving regimens that include irinotecan. Our goal is to provide patients with early warnings that they are likely high irinotecan metabolizers, thereby enabling prophylactic diarrheal treatment and closer monitoring by their treatment team. A tantalizing possibility here is to use a dietary carbon source to saturate the drug- interacting carbohydrate active enzymes before patients are given the drug, thereby reducing the number of patients who suspend treatment due to severe adverse events.

Alexander Kostic
Assistant Professor
Harvard Medical School

Yang-Yu Liu
Assistant Professor of Medicine
Harvard Medical School

Yangcong Zhang
Postodoctoral Fellow Huttenhower Lab
Harvard T.H. Chan School of Public Health

Nathan Crook
Assistant Professor – Chemical & Biomolecular Engineering
NC State

Dr. Crook received his PhD in Chemical Engineering at the University of Texas at Austin in 2014 under the guidance of Hal Alper, where he focused on developing novel genetic engineering techniques for Saccharomyces cerevisiae.  He then undertook postdoctoral studies at Washington University in Saint Louis in the laboratory of Gautam Dantas, where he studied the evolutionary trajectories of probiotic bacteria in the mammalian gut.  The Crook Lab develops new high-throughput experimental and computational genetic engineering techniques. In doing so, his lab hopes to uncover novel biological phenomena and accelerate applied research and development in the broad areas of metabolic engineering, synthetic biology, and microbial ecology.

Aida Habtezion
MD, Principal Investigator
Stanford University

Dr. Habtezion is a physician scientist, appointed as the endowed Ballinger-Swindells Scholar, Tenured Associate Professor in the Department of Medicine, Division of Gastroenterology & Hepatology and Institute for Immunity, Transplantation and Infection, and Associate Dean for Academic Affairs at Stanford School of Medicine. She is a fellow of the Stanford ChEM-H (Chemistry, Engineering & Medicine for Human Health), member of the Stanford Neuroscience Institute, Stanford Cancer Institute, Stanford Pancreas Cancer Research Group, and Stanford Diabetes Research Center. Her research supported by the NIH, Department of Defense, and foundation grants aims to understand immune signaling and pathways in diseases affecting the pancreas and the intestine with hopes of finding therapeutic targets that can be translated to clinical care. In 2011-2012 she was named digestive disease investigator and in 2012-2015 she received the Robert Wood Johnson Harold Amos Medical Faculty Development Award. In 2013 she received the Division of Gastroenterology & Hepatology Teaching Award and in 2016 the Immunology Faculty Mentor of the Year. In 2017, she received Synergy Award from the Kenneth Rainin Foundation for her research in inflammatory bowel disease (IBD), she was elected into the American Society for Clinical Investigation and also into the American Pancreas Association Council.

Betty Theriault
DVM, Assistant Professor
University of Chicago

Dr. Betty Theriault is Director of the University of Chicago Gnotobiotic Research Animal Facility. She holds a faculty appointment as Professor in the Department of Surgery and Clinical Veterinarian within the Animal Resources Center at The University of Chicago. She is a veterinarian with over thirty years of experience working with animals in a variety of settings and across a broad spectrum of species. Her work focuses on assisting researchers develop animal models of human disease and adapting technologies to unique applications. She has been primary or co-author to publications spanning a diverse range of models and species including but not limited to animal models of transplantation, ovarian cancer metastasis, food allergy, circadian rhythm and obesity. She is past President of the recently revitalized Association for Gnotobiotics, and current President of the International Association for Gnotobiology. Dr. Theriault has presented lectures on topics of gnotobiology at scientific meetings locally, nationally and internationally and has led gnotobioticfocused workshops annually at national American Association for Laboratory Animal Science (AALAS) meetings for the past several years. She received her Doctorate in Veterinary Medicine from the University of California at Davis. She is a Diplomate of the American College of Laboratory Animal Medicine.

Nichole Klatt
Professor, Director, Division of Surgical Outcomes and Precision Medical Research
University of Minnesota

Lynn Bry
Massachusetts Host Microbiome Center

Shirley Tsunoda
Professor of Clinical Pharmacy
UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences

Arthur Dobbe
(Bio)Process Engineer
Wacker Biotech

Stacy Kahn
MD, Attending Physician
Boston Children’s Hospital

Dr. Stacy Kahn completed her undergraduate degree in history at Washington University in St. Louis, and her post-baccalaureate premedical training at Bryn Mawr College in Pennsylvania. She attended New York University School of Medicine and then went on to complete her pediatric residency and pediatric gastroenterology fellowship at the University of Chicago. While at the University of Chicago, she also completed an ethics fellowship at the Maclean Center for Clinical Medical Ethics. Clinically, Dr. Kahn’s interests have focused on the care of children with IBD, in particular she is interested in the care and management of teens and young adults with Crohn’s and colitis. While on the faculty at the University of Chicago, she founded and was the Director for the Transitional IBD Clinic. Dr. Kahn's other primary clinical focus is recurrent and refractory Clostridium difficile infection. She is a national expert and leader in the field of fecal microbiota transplantation (FMT) and performed the first colonoscopic FMT in a child. Dr. Kahn's research interests include FMT for Clostridium difficile, FMT for inflammatory bowel disease, transition of care and self-management in IBD and research ethics. She is the director of the FMT research program at Boston Children’s Hospital and has led the development of the first national pediatric FMT registry.

Jessica Allegretti
MD, Director Clinical Trials
Brigham & Women’s Hospital

Dr. Jessica Allegretti graduated from Cornell University in Ithaca New York, and The Miller School of Medicine at the University of Miami in Miami, Florida. She was trained in internal medicine at Massachusetts’s General Hospital and completed her gastroenterology fellowship training at Brigham and Women’s Hospital. She later went on to receive a Master of Public Health degree from the Harvard School of Public Health. Currently she is an attending gastroenterologist at the Brigham and Women’s Hospital Crohn’s and Colitis Center, where she also serves as the center’s Director of Clinical Trials. In addition to her clinical responsibilities and caring for patients with IBD, Dr. Allegretti is the director of the fecal microbiota transplant program at Brigham and Women’s Hospital. She is currently leading several clinical trials investigating the use of fecal transplantation in several chronic diseases such as inflammatory bowel disease, primary sclerosis cholangitis and obesity. Additionally, Dr. Allegretti’s research focuses on investigating the mechanisms of recurrent clostridium difficile infections.

Day Two

Thursday 13th December 2018

3:30 pm | Designing and Executing FMT Clinical Trials

Sahil Khanna
MD, Associate Professor of Medicine & Consultant
Mayo Clinic

The research program of Sahil Khanna, M.B.B.S., focuses on the epidemiology, risk factors and treatment of Clostridium difficile infection (CDI). As the most common infection in hospitals, CDI is an urgent public health threat with high mortality and recurrence rates. With an epidemic of this infection seen in the community, there is an emergent need to study the epidemiology and novel risk factors. Dr. Khanna leads Mayo Clinic's clinical and research program involving fecal microbiota transplantation for CDI, performs clinical trials for treatment of CDI, and studies the role of the gut microbiome in the management and outcomes of CDI.

Jonathan Peled
Memorial Sloan Kettering Cancer Center

After his medical residency at Massachusetts General Hospital in Boston and heme/onc fellowship at Memorial Sloan Kettering Cancer Center, Jonathan joined the Adult Bone Marrow Transplantation Service of MSKCC where he serves as an Assistant Attending. He studies how the intestinal microbiota interact with the host immune system as it relates to hematopoietic stem-cell transplantation, with a particular interest in graft-vs-tumor activity and graft-vs-host disease.

Eric Smith

Day Two

Thursday 13th December 2018

10:30 am | A Trifecta in Microbiome Advancements: Expectations from the Partnership of Diversigen, Corebiome and DNA Genotek